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Background: Cystic ﬁbrosis-related diabetes (CFRD) is correlated with a decline in lung function. Under certain circumstances, oral glucose
tolerance test (OGTT) screening, used to diagnose CFRD, fails to reveal early glucose tolerance abnormalities. In this situation, continuous glucose
monitoring (CGM) could be a useful tool for evaluating early abnormalities of glucose tolerance in CF patients. We aimed to study the CGM
glucose proﬁle in CF patients with normal OGTT screening results and to evaluate lung function and nutritional status according to the CGM
glucose proﬁle.
Methods: We assessed glycemic control, the CGM glucose proﬁle, nutritional status, lung function antibiotic courses and colonization (P. aeruginosa
and S. aureus) in CF patients, aged 10 years and over, with normal screening OGTT results (blood glucose at T120 min b 7.8 mmol/l). Two groups
were identiﬁed according to the max CGM glucose value: Group 1 b 11 mmol/l and Group 2 ≥ 11 mmol/l.
Results: Among the 38 patients with normal OGTT, 12 (31.6%) were in Group 2. Compared to Group 1, Group 2 patients exhibited a signiﬁcant
impairment in lung function: FEV1, 68.2 ± 25.6% vs. 87.3 ± 17%, p = 0.01 and FVC, 86.1% ± 19.4% vs. 99.3% ± 13.4%, p = 0.021, as well
as a higher rate of colonization by P. aeruginosa: 83.3% vs. 44%, p = 0.024. Nevertheless, there were no differences in nutritional status (BMI
standard deviation score: p = 0.079; prealbumin: p = 0.364).
Conclusions: CGM reveals early abnormalities of glucose tolerance that remain undiagnosed by OGTT screening and are associated with worse
lung function and a higher prevalence of P. aeruginosa colonization in patients with CF.
Clinical trial registration number: NCT00476281.
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Because the life expectancy of cystic fibrosis (CF) patients
has increased over the past few decades, cystic fibrosis-related
diabetes (CFRD) has become a common complication of CFby Elsevier B.V. All rights reserved.
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to be associated with an impairment of lung function [2,3] and
weight loss [4]; both are associated with higher mortality rates
[5–7].
For the early detection of CFRD and improvements in its
treatment, OGTT is recommended in the North American
Cystic Fibrosis Foundation criteria [1] to be performed yearly
on patients older than 10 years of age. However, some authors
have shown that the standard methods of glycemic assessment,
random or fasting glucose concentrations, and/or OGTT under-
diagnosed CFRD [8–10]. Consequently, early glucose abnor-
malities remained undetected. Moreover, it is known that patients
who will later develop CFRD present a decrease in their lung
function and weight standard deviation score (SDS) during the
preceding 12 months [11].
CGM is a new method that can be used to evaluate the blood
glucose profile over several days. It was used to control the
efficiency of insulin pump therapy or the self-management of
type 1 diabetic patients at home [12–14]. It has also been
evaluated in children, adolescents and adults with CF [15,16],
and its use has been proposed to study early glucose tolerance
abnormalities [17–19]. As a result, it could be a useful tool to
diagnose early glucose abnormalities that are not revealed by
OGTT.
We designed this study to assess CGM glucose profiles in CF
patients with normal OGTT. Nutritional status, lung function and
infection parameters were studied in CF patients according to
their CGM glucose profile.
2. Methods
2.1. Study design and patients
A total of 83 CF patients (42 males and 41 females) with
fasting glycemia b 6.9 mmol/l who were at least 10 years old
(age range: 12.4–57.3 years) were followed at the CF center
of Strasbourg University Hospital (France) and enrolled in a
prospective monocentric cross-sectional cohort study between
March 2009 and September 2012. The CF diagnosis in these
patients was based on clinical features and on positive CF
genotype. The subjects were excluded if they had been diag-
nosed with diabetes or liver disease, had undergone a lung
transplant or were taking steroids. Each patient underwent
blood tests (HbA1c and prealbumin), OGTT, CGM, respiratory
and nutritional evaluation. The evaluations were performed
while the patients were in a clinically stable state, with at least
1 month having passed since any respiratory exacerbation and
in the absence of a restricted-calorie diet. The protocol was
approved by the local ethics committee (n.2007/09), and each
patient or their legal representative provided written informed
consent. The study protocol was conducted in accordance with
the Declaration of Helsinki.
2.2. Metabolic evaluation
The OGTT screening was performed at the CF center on the
morning after an unrestricted diet and typical physical activity.As recommended by the World Health Organization criteria
[20] and the North American Cystic Fibrosis Foundation cri-
teria [1], plasma glucose and C-peptide levels were measured
at 0 and 120 min after drinking a glucose solution at a dose
of 1.75 g/kg (up to a maximum of 75 g). The patients were
classified according to the level of glycemia they presented at 2 h:
normal glucose tolerance (NGT), glycemia at 2 h b 7.8 mmol/l;
impaired glucose tolerance (IGT), 7.8 mmol/l ≤ glycemia at
2 h b 11 mmol/l; and CFRD, glycemia at 2 h ≥ 11 mmol/l.
The HbA1c (hemoglobin A1c) level was determined before
performing the OGTT (%) using high-performance liquid chro-
matography (Variant 2, Bio-Rad, Marnes-La-Coquette, France).
Within three months after the OGTT was performed, patients
remained stable in terms of weight, did not show pulmonary
exacerbations requiring steroid intake, and had the CGM device
installed at the outpatient clinic (Medtronic, and Sylmar, CA,
USA). This device remained in situ in the home environment for
72 h for all of the subjects. They consumed their typical diet and
entered a minimum of four self-monitored blood glucose values
for daily CGM calibration. Various parameters were assessed:
average glucose (mmol/l), maximum glucose (mmol/l), AUC of
glucose values ≥ 7.8 mmol/l (mmol/l/day), duration of glucose
values ≥ 7.8 mmol/l over the course of 72 h (%) and peak
number of interstitial glucose values ≥ 11 mmol/l. We defined
two groups based on the presence (Group 1) or absence (Group 2)
of at least one interstitial glucose value higher than 11 mmol/l
during the CGM recording.
2.3. Nutritional status
Patients were weighed and measured, and their BMI [weight
in kilograms/height in meters squared] was calculated. The
age- and gender-specific z-scores for BMI SDS (SD: standard
deviation) were computed relative to the French reference popu-
lation [21]. A blood sample was taken just before the OGTT to
determine the prealbumin level (g/l).
2.4. Lung function
The patients performed spirometry with FEV1 and FVC
measurements (Vmax spirometer, VIASYS, Healthcare Respira-
tory Technologies, Canada), which was adjusted in percentage
according to the age, gender, height and weight, as recommended
by the ERS (European Respiratory Society) and the North
American (American Thoracic Society) guidelines [22]. The
number of intravenous antibiotic courses in one year was quan-
tified for each subject. The bacterial species in sputum specimens
(P. aeruginosa and S. aureus) were identified according to the
North American guidelines [23].
2.5. Statistical analysis
All of the data were extracted from the CGM sensor to a
personal computer with the aid of a communication device,
which allowed downloading and reviewing (MiniMed Solu-
tions Software, version 1.7a). The mean and SD of the inter-
stitial glucose concentrations were derived for all of the CGM
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using chi-squared tests or Fisher's exact tests. Continuous
variables were analyzed using the Student's t-tests or the
Wilcoxon's test, as appropriate. Correlations among variables
were calculated using the Pearson's correlation coefficient or
Spearman's rank correlation. In multivariate analysis, variables
found to be statistically significant in bivariate analyses (age,
age at diagnosis, sex, genotype, exocrine pancreatic insuffi-
ciency, BMI SDS, and P. aeruginosa colonization) were
included as potential covariates. Analyses were performed
using GraphPad Prism, version 5.0 and the R statistical soft-
ware, version 3.0.2. The data are expressed as the mean values
with standard deviation where appropriate. Significance was set
at the 5% level.
3. Results
3.1. Study design and patients
Of the 83 initially selected patients with CF, 15 were
excluded: 6 were diabetic prior to inclusion, 7 were lost to
follow-up, and 2 revoked their consent. Then, 16 of the 68
remaining patients underwent OGTT only. The remaining 52
(59.6% female) underwent both OGTT and CGM. The average
age was 26.6 ± 9.76 years; the age upon diagnosis of CF was
9.38 ± 12.6 years (means ± SD), and 84.2% of the subjects
presented exocrine pancreatic insufficiency. A total of 32.7% of
the patients were homozygous F508Del, 34.6% were hetero-
zygous for F508Del, and 32.7% presented other mutations. Of
these 52 patients, 38 were NGT, and 14 had glucose tolerance
abnormalities (IGT: n = 9, CFRD: n = 5). The study design is
shown in Fig. 1.
In the 38 patients with normal OGTT (NGT), the BMI
SDS was 0.88 ± 1.52 SD, and the prealbumin concentration
was 0.25 ± 0.05 g/l. FEV1 and FVC were 82% ± 22.2%
(2.62 ± 0.89 l) and 96 ± 17.4% (3.64 ± 1.12 l), respectively.Fig. 1. StudyThe characteristics of the NGT groups are described in Table 1.
A total of the 38 patients with normal OGTT was evaluated.
Of these, 12 patients (31.6%) had at least one interstitial glu-
cose greater than 11 mmol/l (Group 2). The other 26 patients
who had no interstitial glucose value ≥ 11 mmol/l composed
Group 1.
The patients in Group 1 (n = 26) had a mean age of 27.2 ±
10.7 years and were predominantly female (57.7%). The age at
diagnosis of CF was 12.25 ± 14.12 years old, and 76.9% had
exocrine pancreatic insufficiency. With respect to mutations,
30.8% patients were homozygous for F508Del, 53.8% were
heterozygous for F508Del, and 15.4% had other mutations.
Group 2 (n = 12) was 66.7% female, and the mean age was
23.53 ± 6.9 years. With respect to the age at CF diagnosis, the
patients in Group 2 were significantly younger than those in
Group 1: 3.16 ± 4.75 vs. 12.25 ± 14.12 years, respectively
(p = 0.037). All of the patients in Group 2 had exocrine
pancreatic insufficiency. Additionally, 50% of the patients were
homozygous for F508Del, 25% were heterozygous for F508Del,
and 25% had other mutations. There were no differences with
respect to age, sex ratio, genetic status or exocrine pancreatic
insufficiency (p = 0.07) between the two groups. The character-
istics of the patients are summarized in Table 1.
3.2. Metabolic evaluation
Analyses of the OGTT between these two groups revealed
no significant differences in the C peptide plasma levels at
T0 min or at T120 min. There was a tendency toward a higher
HbA1c in Group 2 compared with Group 1 (p = 0.055).
In Group 2, the CGM revealed a significantly higher
AUC ≥ 7.8 mmol/l (3.42 ± 2.27 vs. 0.39 ± 0.57 mmol/l/day,
p b 0.0001) and a longer percentage of time with interstitial
glucose ≥ 7.8 mmol/l: (14.17% ± 10.38% vs. 3.54% ± 3.99%,
p b 0.0001). However, the average interstitial glucose did not
differ between the two groups (p = 0.067).design.
Table 1
Baseline characteristics of the patients. Group 1: CGM max b 11 mmol/l, Group 2: CGM max ≥ 11 mmol/l. p values refer to the comparison between Group 1 and
Group 2. NS: Not significant. ND: Not done.
Total Group 1 Group 2 p
No. of patients (%) 38 26 12
Female 23 (60.5%) 15 (57.7%) 8 (66.7%) NS
Age at evaluation (years) 26.05 ± 9.76 27.21 ± 10.7 23.53 ± 6.9 NS
Age at diagnosis of CF (years) 9.38 ± 12.6 12.25 ± 14.12 3.16 ± 4.75 0.037
Genotype (% of patients)
-Homozygous F508Del 36.8 30.8 50 NS
-Heterozygous F508Del 44.8 53.8 25 NS
-Other mutations 18.4 15.4 25 NS
Exocrine pancreatic insufficiency 32 (84.2%) 20 (76.9%) 12 (100%) 0.07
OGTT
Glycemia T0 min (mmol/l) 4.73 ± 0.44 4.67 ± 0.33 4.73 ± 0.44 NS
Glycemia T120 min (mmol/l) 5.01 ± 1.43 5.66 ± 1.15 5.94 ± 1.1 NS
C-peptide plasma level T0 min (μg/l) 1.67 ± 0.57 1.77 ± 0.55 1.46 ± 0.60 NS
C-peptide plasma level T120 min (μg/l) 6.92 ± 2.34 6.85 ± 1.90 7.07 ± 3.12 NS
HbA1c (%) 5.66 ± 0.33 5.58 ± 0.35 5.81 ± 0.24 0.055
CGM
Average interstitial glucose (mmol/l) 5.79 ± 0.80 5.61 ± 0.82 6.10 ± 0.60 NS
AUC ≥ 7.8 mmol/l/day 1.34 ± 1.94 0.39 ± 0.57 3.42 ± 2.27 b0.0001
% time ≥ 7.8 mmol/l 6.89 ± 8.24 3.54 ± 3.99 14.17 ± 10.38 b0.0001
No. of peaks with interstitial glucose ≥ 11 mmol/l 0.42 ± 0.76 0 1.08 ± 0.2 ND
No. of IV antibiotic courses/year 0.82 ± 1.16 0.68 ± 1.14 1.17 ± 1.27 NS
Prevalence (%)
P. aeruginosa 55.3 44 83.3 0.024
S. aureus 76.3 84.6 58.3 0.076
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OGTT is shown in Fig. 2. Glucose peaks higher than 7.8 mmol/l
were present after each meal for 3 days. This patient wasFig. 2. CGM recording in a patient with normal OGTT results. Pathological CGM rec
blue) in a patient with normal OGTT results. Several interstitial glucose peaks higher
glucose higher than 200 mg/dl (11 mmol/l) was present on Sunday evening.classified into Group 2 because he had one glucose peak that was
higher than 11 mmol/l on Sunday evening. The average glycemia
was 6.1 mmol/l, and the maximal glycemia was 20.6 mmol/l.ordings over the course of three days (Saturday: brown; Sunday: black; Monday:
than 140 mg/dl (7.8 mmol/l) are present after each meal. One peak of interstitial
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16% of 72 h (i.e., 11.52 h), and the AUC ≥ 7.8 mmol/l was
22 mmol/l/day.
3.3. Nutritional status
There was no difference between the patients in Groups 1
and 2 with respect to the BMI SDS (1.75 ± 2.17 SD vs.
0.34 ± 1.06 SD, p = 0.079) or prealbumin concentration
(0.256 ± 0.044 g/l vs. 0.239 ± 0.052 g/l, NS; Fig. 3A and B,
respectively).
3.4. Lung function and bronchopulmonary infections
FEV1 and FVC were significantly lower in the Group 2
patients compared to the Group 1 patients independent of age,
age at diagnosis, sex, genotype, exocrine pancreatic insufficiency,
BMI SDS, and P. aeruginosa colonization: 68.2% ± 25.6%
(2.20 ± 0.88 l) vs. 87.3% ± 17% (2.82 ± 0.84 l) (p = 0.01) and
86.1% ± 19.4% (3.26 ± 1.08 l) vs. 99.3% ± 13.4% (3.82 ±
1.11 l) (p = 0.021), respectively (Fig. 3C and D). There
was no difference in the number of intravenous antibiotic
courses (p = 0.24) between the two groups. With respect toA














































Fig. 3. BMI SDS (A.), prealbumin (B.), FEV1 (C.), and FVC (D.) in cystic
fibrosis patients with normal OGTT and CGM glucose values b 11 mmol/l
(Group 1) or ≥11 mmol/l (Group 2) *p b 0.05; **p b 0.001.bacterial colonization, Group 2 patients were more frequently
colonized by P. aeruginosa (83.3% vs. 44%, p = 0.024)
independent of age, age at diagnosis, sex, genotype, exocrine
pancreatic insufficiency, and BMI SDS. S. aureus coloniza-
tion appeared to be less common in Group 2 (p = 0.076).
4. Discussion
We have shown that early abnormalities in glucose tol-
erance, which were detected by CGM but not conventional
OGTT, were associated with lung function impairment in CF
patients.
In agreement with other studies [16,17,19], we observed that
approximately one third of the patients with normal OGTT
results, according to the WHO criteria [20], presented early
abnormalities according to a CGM glucose profile (glucose
value above 11 mmol/l).
The explanation of why OGTT screening underdiagnosed
these early abnormalities in glucose tolerance has previously
been studied. Dobson et al. have shown that, despite having
similar fasting and 120-min glucose values, non-diabetic CF
patients reach higher glucose values at the intermediate point
during OGTT and exhibit an increased AUC in blood glucose
values compared to non-diabetic non-CF patients [8]. No
significant difference was observed between NGT patients and
CFRD patients. Furthermore, glucagon-like peptide 1 (GLP-1),
an incretin hormone released from intestinal L-cells in response
to eating, is known to induce insulin secretion. Hillman et al.
have shown that the GLP-1 level is lower in non-diabetic CF
patients compared to normal patients, but no difference has
been observed in CFRD patients [24]. Additionally, early
glucose abnormalities in CF patients are due to beta-cell
dysfunction and reduced early insulin secretion rather than
insulin resistance [25]. Secondary to this alteration in early
insulin secretion, CF patients with no known glucose abnor-
malities exhibit blood glucose peaks that are higher than those
of CF patients without glucose abnormalities during OGTT
screening. In our study, this reduced early insulin secretion
was also responsible for the postprandial glucose peak greater
than 7.8 mmol/l that was observed in the CGM glucose profile.
The durations of these two types of glucose peak profiles
(OGTT, post-prandial) were similar (approximately 90 min).
Finally, in contrast to OGTT screening (which was typically
not associated with the intermediate glucose value), CGM,
a more physiological tool, allowed the diagnosis of early
abnormalities in glucose tolerance due to alterations in early
insulin secretion.
Therefore, in our study, CGM revealed high glucose value
excursions that were not observed in the OGTT, whereas there
was no difference in the mean glucose values between the two
groups. However, the AUCs above 7.8 mmol/l and the duration
of the hyperglycemic period (%) were higher in patients with
glucose values above 11 mmol/l. These two parameters have
previously been reported to be higher in CFRD patients com-
pared to those in NGT and IGT patients, although no difference
has been reported between NGT and IGT [17]. Khammar et al.
compared the CGM glucose profiles in non-CFRD patients
483A. Leclercq et al. / Journal of Cystic Fibrosis 13 (2014) 478–484(blood glucose T120 min b 2 g/l at OGTT) according to the
presence of high interstitial glucose values above 11 mmol/l.
The duration of the hyperglycemic period was also significantly
longer in patients with a high number of glucose values above
11 mmol/l [24]. Consequently, three CGM parameters (an
AUC above 7.8 mmol/l, duration of the hyperglycemic period
(%) and interstitial glucose values above 11 mmol/l) can be
used to study the early abnormalities of glucose tolerance in CF
patients.
In our study, HbA1c was comparable between the two
groups, although it appeared to be higher in patients with a
greater number of glucose values above 11 mmol/l. A few
explanations regarding how HbA1C can remain normal for
such a long time in CFRD patients have been discussed in
the literature. First, the lifespan of red blood cells is reduced
in CF patients [27]. Second, due to the effect on early insulin
secretion, early glucose tolerance abnormalities may particu-
larly affect postprandial glucose (PPG) in CF patients, with less
effect on the mean glucose value according to CGM. Moreover,
in type 2 diabetic patients, some authors have observed that the
fasting plasma glucose (FPG) level is the strongest predictor of
HbA1c [28]. In fact, Monnier et al. showed that in patients with
type 2 diabetes, HbA1c was linked in different ways to PPG or
FPG according to the severity of diabetes [29]. Indeed, PPG
was the predominant contributor in patients who maintained
satisfactory to good control of their diabetes, whereas the
contribution of FPG increased as diabetes worsened. Further-
more, PPG was a better predictor of good or satisfactory control
of diabetes (HbA1c b 7%) compared to FPG. Consequently,
HbA1c appeared to be linked to PPG due to the early ab-
normalities of glucose tolerance. However, according to the
recommendations regarding CFRD [1], HbA1c is not an ap-
propriate parameter to identify CF subjects who present early
abnormalities in glucose tolerance.
Because CFRD has been associated with impaired lung
function and poor nutritional status, many studies have used
CGM to detect early abnormalities in glucose tolerance in
CF patients. Even if these studies have shown that patients
with normal OGTT can exhibit early abnormalities in glucose
tolerance using the CGM glucose profile [17–19,26], none
have shown an association with lower FEV1 and FVC values
and a higher level of colonization with P. aeruginosa.
It is already known that overt CFRD is a potential risk factor
for decreased lung function [3]. Our study demonstrates that
even early abnormalities in glucose tolerance could also be a
risk factor for impaired lung function. In a retrospective study,
Alicandro et al. demonstrated that CF patients with normal
OGTT and lower insulin secretion had worse lung function.
Similar results were observed for CF patients with a higher
AUC for the glucose concentration, but no difference was
observed using the number of blood glucose peaks above
8.14 mmol/l (OGTT) [30].
The fact that the C peptide plasma level was not different
between our two groups can be explained. For example,
compared to Alicandro et al., the C peptide plasma level was
only measured at T0 min and T120 min. These data agreed
with the hypothesis that alterations of early insulin secretion,undetected by the OGTT, were associated with worse lung
function.
Repeated infections by P. aeruginosa are also known to be
a risk factor for poor lung function. The frequency of these
infections is increased with CFRD [3]. Moreover, Brennan
et al. have demonstrated in CF patients that airway glucose
concentrations are dependent on the blood glucose and that
P. aeruginosa growth increases if the airway glucose is above
1–4 mmol/l [31]. Consequently, these data can explain why CF
patients with early abnormalities in glucose tolerance were
more frequently colonized by P. aeruginosa.
Malnutrition is also a risk factor for worse lung function,
and nutritional status is linked to glucose abnormalities. The
nutritional status is generally worse in CF patients with CFRD
[4]. According to the literature, during the preceding 12 months
of CFRD, CF patients already exhibit a decline in the weight
standard deviation score (SDS) [11]. Moreover, CF patients
with normal OGTT results and lower insulin secretion had a
lower BMI SDS [30]. However, in accordance with our study,
Alicandro et al. failed to observe a difference in the BMI SDS
using the AUC concentration of glucose or the blood glucose
peak above 8.14 mmol/l. Consequently, early abnormalities
in the glucose profile did not appear to be associated with
impaired nutritional status. Indeed, Hameed et al. did not show
a difference in the weight SDS during the preceding 12 months
between NGT and IGT patients [11]. Our findings suggest that,
contrary to the nutritional status, lung function might be more
sensitive to early abnormalities in the glucose tolerance of CF
patients.
Some interesting points can be made regarding our popu-
lation. Even if there was no difference in age between the
patients with and without glucose abnormalities, the age at
diagnosis of CF was higher in patients without early abnor-
malities in glucose tolerance. Age at diagnosis has also been
shown to significantly affect FEV1 (p b 0.0001), but this result
was not clinically relevant (under the 10% threshold after
making adjustments for age, BMI, pancreatic status, chronic
P. aeruginosa infection and CFRD) [3]. Therefore, CF patients
diagnosed at a later age could have better lung function and
develop the early abnormalities of glucose tolerance later than
others.
Pancreatic insufficiency has also been shown to be a risk
factor for poor lung function [3]. In our study, compared to
three quarters of the patients with normal glucose tolerance, all
of the patients with early abnormalities of glucose tolerance
also exhibited pancreatic exocrine insufficiency, although there
was no significant difference. These findings suggest an im-
portant role of global pancreatic cell dysfunction in lung func-
tion impairment and glucose abnormality.
According to our main hypothesis, alterations in pancreatic
function (particularly early insulin secretion dysfunction) in CF
patients with normal OGTT screening could be revealed using
CGM, thanks to the early blood glucose peak present after a
meal or glucose intake.
One limitation of our study is the relatively small number
of patients in the cohort. The flow chart indicates that only half
of the patients initially recruited were ultimately included in the
484 A. Leclercq et al. / Journal of Cystic Fibrosis 13 (2014) 478–484analysis. However, because these patients were thoroughly
evaluated, it appears unlikely that increasing the number of
patients could change the main findings of this study.
In conclusion, CGM revealed early abnormalities of glucose
tolerance that had remained undiagnosed by OGTT screening
and that were associated with impaired lung function and a
higher prevalence of P. aeruginosa colonization in patients
with CF. Further studies with a larger sample size are needed to
confirm our results. Such studies may confirm the usefulness of
CGM in the diagnosis of early glucose abnormalities and the
prevention impaired lung function.
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